louisiana glp-1 gastric stasis class action spent over $1B on GLP-1s in 2023. See U.S. data Mounjaro® Stomach Paralysis Lawsuit |

Somatostatin analog SMS 201995 (octreotide) as a possible solution to the dumping syndrome after gastrectomy or vagotomy

Sema 2.4 mg for the treatment of obesity: A review of the STEP 15 trials

For Medicare beneficiaries, the differences are particularly important to understand

The market covers pharmaceutical interventions, minimally invasive and surgical procedures, nutritional support therapies, and emerging device-based treatments designed to improve gastric motility, reduce symptoms (nausea, vomiting, bloating, abdominal pain), and enhance patient quality of life

Errors in either dimension render the medication ineffective or unsafe

How does the Precision Peptide Genetic Test help with semaglutide storage concerns